220 related articles for article (PubMed ID: 19147749)
1. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator.
Bin Hafeez B; Adhami VM; Asim M; Siddiqui IA; Bhat KM; Zhong W; Saleem M; Din M; Setaluri V; Mukhtar H
Clin Cancer Res; 2009 Jan; 15(2):452-9. PubMed ID: 19147749
[TBL] [Abstract][Full Text] [Related]
2. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of ETV4 is associated with poor prognosis in prostate cancer: involvement of uPA/uPAR and MMPs.
Qi M; Liu Z; Shen C; Wang L; Zeng J; Wang C; Li C; Fu W; Sun Y; Han B
Tumour Biol; 2015 May; 36(5):3565-72. PubMed ID: 25544710
[TBL] [Abstract][Full Text] [Related]
4. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor.
Raghu H; Gondi CS; Dinh DH; Gujrati M; Rao JS
Mol Cancer; 2011 Oct; 10():130. PubMed ID: 22004682
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of Notch1 inhibits nasopharyngeal carcinoma cell growth and metastasis via downregulation of CCL2, CXCL16, and uPA.
Guo H; Wang F; Diao Y; Zhang Z; Chen Q; Qian CN; Keller ET; Zhang J; Lu Y
Mol Carcinog; 2019 Oct; 58(10):1886-1896. PubMed ID: 31270884
[TBL] [Abstract][Full Text] [Related]
7. PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-κB- and HDAC1-mediated expression and activation of uPA.
Zou Z; Zeng F; Xu W; Wang C; Ke Z; Wang QJ; Deng F
J Cell Sci; 2012 Oct; 125(Pt 20):4800-11. PubMed ID: 22797919
[TBL] [Abstract][Full Text] [Related]
8. Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.
Shi C; Zhang N; Feng Y; Cao J; Chen X; Liu B
Cell Physiol Biochem; 2017; 41(4):1313-1324. PubMed ID: 28278500
[TBL] [Abstract][Full Text] [Related]
9. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
10. Gelsolin induces colorectal tumor cell invasion via modulation of the urokinase-type plasminogen activator cascade.
Zhuo J; Tan EH; Yan B; Tochhawng L; Jayapal M; Koh S; Tay HK; Maciver SK; Hooi SC; Salto-Tellez M; Kumar AP; Goh YC; Lim YC; Yap CT
PLoS One; 2012; 7(8):e43594. PubMed ID: 22927998
[TBL] [Abstract][Full Text] [Related]
11. CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer.
Xie C; Jiang XH; Zhang JT; Sun TT; Dong JD; Sanders AJ; Diao RY; Wang Y; Fok KL; Tsang LL; Yu MK; Zhang XH; Chung YW; Ye L; Zhao MY; Guo JH; Xiao ZJ; Lan HY; Ng CF; Lau KM; Cai ZM; Jiang WG; Chan HC
Oncogene; 2013 May; 32(18):2282-91, 2291.e1-7. PubMed ID: 22797075
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer.
Kong D; Li Y; Wang Z; Banerjee S; Sarkar FH
Cancer Res; 2007 Apr; 67(7):3310-9. PubMed ID: 17409440
[TBL] [Abstract][Full Text] [Related]
13. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells.
Pang RT; Leung CO; Ye TM; Liu W; Chiu PC; Lam KK; Lee KF; Yeung WS
Carcinogenesis; 2010 Jun; 31(6):1037-44. PubMed ID: 20351093
[TBL] [Abstract][Full Text] [Related]
15. Reciprocal regulation of long noncoding RNAs THBS4‑003 and THBS4 control migration and invasion in prostate cancer cell lines.
Liu J; Cheng G; Yang H; Deng X; Qin C; Hua L; Yin C
Mol Med Rep; 2016 Aug; 14(2):1451-8. PubMed ID: 27357608
[TBL] [Abstract][Full Text] [Related]
16. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells.
Subramanian R; Gondi CS; Lakka SS; Jutla A; Rao JS
Int J Oncol; 2006 Apr; 28(4):831-9. PubMed ID: 16525631
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.
Dong Z; Saliganan AD; Meng H; Nabha SM; Sabbota AL; Sheng S; Bonfil RD; Cher ML
Neoplasia; 2008 May; 10(5):439-49. PubMed ID: 18472961
[TBL] [Abstract][Full Text] [Related]
18. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition.
Oh SH; Lee OH; Schroeder CP; Oh YW; Ke S; Cha HJ; Park RW; Onn A; Herbst RS; Li C; Lee HY
Mol Cancer Ther; 2006 Nov; 5(11):2685-95. PubMed ID: 17121915
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.
Gondi CS; Lakka SS; Dinh DH; Olivero WC; Gujrati M; Rao JS
Clin Cancer Res; 2007 Jul; 13(14):4051-60. PubMed ID: 17634529
[TBL] [Abstract][Full Text] [Related]
20. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
